Cargando…
Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity
Conventional serum antibody titer, which expresses antibody level, does not provide antigen binding avidity of the variable region of the antibody, which is essential for the defense response to infection. Here, we quantified anti-SARS-CoV-2 antibody binding avidity to the receptor-binding domain (R...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459795/ https://www.ncbi.nlm.nih.gov/pubmed/37632005 http://dx.doi.org/10.3390/v15081662 |
_version_ | 1785097497575686144 |
---|---|
author | Takahashi, Etsuhisa Sawabuchi, Takako Homma, Tetsuya Fukuda, Yosuke Sagara, Hironori Kinjo, Takeshi Fujita, Kaori Suga, Shigeru Kimoto, Takashi Sakai, Satoko Kameda, Keiko Kido, Hiroshi |
author_facet | Takahashi, Etsuhisa Sawabuchi, Takako Homma, Tetsuya Fukuda, Yosuke Sagara, Hironori Kinjo, Takeshi Fujita, Kaori Suga, Shigeru Kimoto, Takashi Sakai, Satoko Kameda, Keiko Kido, Hiroshi |
author_sort | Takahashi, Etsuhisa |
collection | PubMed |
description | Conventional serum antibody titer, which expresses antibody level, does not provide antigen binding avidity of the variable region of the antibody, which is essential for the defense response to infection. Here, we quantified anti-SARS-CoV-2 antibody binding avidity to the receptor-binding domain (RBD) by competitive binding-inhibition activity (IC50) between SARS-CoV-2 S1 antigen immobilized on the DCP microarray and various RBD doses added to serum and expressed as 1/IC50 nM. The binding avidity analyzed under equilibrium conditions of antigen–antibody binding reaction is different from the avidity index measured with the chaotropic agent, such as urea, under nonequilibrium and short-time conditions. Quantitative determination of the infection-protection potential of antibodies was assessed by ABAT (antigen binding avidity antibody titer), which was calculated by the quantity (level) × quality (binding avidity) of antibodies. The binding avidity correlated strongly (r = 0.811) with cell-based virus-neutralizing activity. Maturation of the protective antibody induced by repeated vaccinations or SARS-CoV-2 infection was classified into three categories of ABAT, such as an initial, low, and high ABAT. Antibody maturity correlated with the clinical severity of COVID-19. Once a mature high binding avidity was achieved, it was maintained for at least 6–8 months regardless of the subsequent change in the antibody levels. |
format | Online Article Text |
id | pubmed-10459795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104597952023-08-27 Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity Takahashi, Etsuhisa Sawabuchi, Takako Homma, Tetsuya Fukuda, Yosuke Sagara, Hironori Kinjo, Takeshi Fujita, Kaori Suga, Shigeru Kimoto, Takashi Sakai, Satoko Kameda, Keiko Kido, Hiroshi Viruses Article Conventional serum antibody titer, which expresses antibody level, does not provide antigen binding avidity of the variable region of the antibody, which is essential for the defense response to infection. Here, we quantified anti-SARS-CoV-2 antibody binding avidity to the receptor-binding domain (RBD) by competitive binding-inhibition activity (IC50) between SARS-CoV-2 S1 antigen immobilized on the DCP microarray and various RBD doses added to serum and expressed as 1/IC50 nM. The binding avidity analyzed under equilibrium conditions of antigen–antibody binding reaction is different from the avidity index measured with the chaotropic agent, such as urea, under nonequilibrium and short-time conditions. Quantitative determination of the infection-protection potential of antibodies was assessed by ABAT (antigen binding avidity antibody titer), which was calculated by the quantity (level) × quality (binding avidity) of antibodies. The binding avidity correlated strongly (r = 0.811) with cell-based virus-neutralizing activity. Maturation of the protective antibody induced by repeated vaccinations or SARS-CoV-2 infection was classified into three categories of ABAT, such as an initial, low, and high ABAT. Antibody maturity correlated with the clinical severity of COVID-19. Once a mature high binding avidity was achieved, it was maintained for at least 6–8 months regardless of the subsequent change in the antibody levels. MDPI 2023-07-30 /pmc/articles/PMC10459795/ /pubmed/37632005 http://dx.doi.org/10.3390/v15081662 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Takahashi, Etsuhisa Sawabuchi, Takako Homma, Tetsuya Fukuda, Yosuke Sagara, Hironori Kinjo, Takeshi Fujita, Kaori Suga, Shigeru Kimoto, Takashi Sakai, Satoko Kameda, Keiko Kido, Hiroshi Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity |
title | Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity |
title_full | Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity |
title_fullStr | Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity |
title_full_unstemmed | Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity |
title_short | Clinical Utility of SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in Monitoring Protective Immunity and Clinical Severity |
title_sort | clinical utility of sars-cov-2 antibody titer multiplied by binding avidity of receptor-binding domain (rbd) in monitoring protective immunity and clinical severity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459795/ https://www.ncbi.nlm.nih.gov/pubmed/37632005 http://dx.doi.org/10.3390/v15081662 |
work_keys_str_mv | AT takahashietsuhisa clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT sawabuchitakako clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT hommatetsuya clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT fukudayosuke clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT sagarahironori clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT kinjotakeshi clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT fujitakaori clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT sugashigeru clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT kimototakashi clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT sakaisatoko clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT kamedakeiko clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity AT kidohiroshi clinicalutilityofsarscov2antibodytitermultipliedbybindingavidityofreceptorbindingdomainrbdinmonitoringprotectiveimmunityandclinicalseverity |